InflaRx NV
NASDAQ:IFRX

Watchlist Manager
InflaRx NV Logo
InflaRx NV
NASDAQ:IFRX
Watchlist
Price: 2.45 USD 9.38% Market Closed
Market Cap: 144.3m USD
Have any thoughts about
InflaRx NV?
Write Note

InflaRx NV
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

InflaRx NV
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
InflaRx NV
NASDAQ:IFRX
Total Receivables
€2.3m
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Total Receivables
€2.3B
CAGR 3-Years
139%
CAGR 5-Years
142%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Total Receivables
€30.8m
CAGR 3-Years
-33%
CAGR 5-Years
8%
CAGR 10-Years
-12%
Immatics NV
NASDAQ:IMTX
Total Receivables
€5.7m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Total Receivables
€171.8m
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
0%
Formycon AG
XETRA:FYB
Total Receivables
€28.3m
CAGR 3-Years
54%
CAGR 5-Years
41%
CAGR 10-Years
N/A
No Stocks Found

InflaRx NV
Glance View

Market Cap
144.3m USD
Industry
Biotechnology

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

IFRX Intrinsic Value
1.95 USD
Overvaluation 20%
Intrinsic Value
Price

See Also

What is InflaRx NV's Total Receivables?
Total Receivables
2.3m EUR

Based on the financial report for Sep 30, 2024, InflaRx NV's Total Receivables amounts to 2.3m EUR.

What is InflaRx NV's Total Receivables growth rate?
Total Receivables CAGR 3Y
37%

Over the last year, the Total Receivables growth was -32%. The average annual Total Receivables growth rates for InflaRx NV have been 37% over the past three years .

Back to Top